FBXO22 是复发性软骨肉瘤的潜在治疗靶点

IF 3.4 2区医学 Q2 Medicine

Journal of Bone Oncology Pub Date : 2024-05-01 DOI:10.1016/j.jbo.2024.100605

Baoquan Xin , Hui Chen , Zhi Zhu , Qiujing Guan , Guangjian Bai , Cheng Yang , WeiWei Zou , Xin Gao , Lei Li , Tielong Liu

{"title":"FBXO22 是复发性软骨肉瘤的潜在治疗靶点","authors":"Baoquan Xin , Hui Chen , Zhi Zhu , Qiujing Guan , Guangjian Bai , Cheng Yang , WeiWei Zou , Xin Gao , Lei Li , Tielong Liu","doi":"10.1016/j.jbo.2024.100605","DOIUrl":null,"url":null,"abstract":"<div><p>Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS. FBXO22 played a significant role in various cancers. However, the role of FBXO22 in Re-CHS remained unclear. Our research demonstrated that suppressing FBXO22 abated the proliferation and migration of CHS cells and facilitated their apoptosis. In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221213742400085X/pdfft?md5=4748719c82c02d032574b97af535fd09&pid=1-s2.0-S221213742400085X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"FBXO22 is a potential therapeutic target for recurrent chondrosarcoma\",\"authors\":\"Baoquan Xin , Hui Chen , Zhi Zhu , Qiujing Guan , Guangjian Bai , Cheng Yang , WeiWei Zou , Xin Gao , Lei Li , Tielong Liu\",\"doi\":\"10.1016/j.jbo.2024.100605\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS. FBXO22 played a significant role in various cancers. However, the role of FBXO22 in Re-CHS remained unclear. Our research demonstrated that suppressing FBXO22 abated the proliferation and migration of CHS cells and facilitated their apoptosis. In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.</p></div>\",\"PeriodicalId\":48806,\"journal\":{\"name\":\"Journal of Bone Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S221213742400085X/pdfft?md5=4748719c82c02d032574b97af535fd09&pid=1-s2.0-S221213742400085X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bone Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S221213742400085X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221213742400085X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

软骨肉瘤（CHS）是一种恶性骨肿瘤，对放疗和化疗均不敏感，且复发率高。然而，复发性软骨肉瘤（Re-CHS）的潜伏机制仍然难以捉摸。在这里，我们发现 FBXO22 在复发性骨肿瘤的临床样本中高表达。FBXO22 在多种癌症中发挥着重要作用。然而，FBXO22 在 Re-CHS 中的作用仍不清楚。我们的研究表明，抑制 FBXO22 可抑制 CHS 细胞的增殖和迁移，并促进其凋亡。此外，抑制 FBXO22 还能提高 Re-CHS 中 PD-L1 的表达。所有这些发现为利用FBXO22和PD-L1作为联合靶点来预防和治疗Re-CHS提供了新的证据，这可能被证明是CHS（尤其是Re-CHS）免疫疗法的一种新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

FBXO22 is a potential therapeutic target for recurrent chondrosarcoma

Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS. FBXO22 played a significant role in various cancers. However, the role of FBXO22 in Re-CHS remained unclear. Our research demonstrated that suppressing FBXO22 abated the proliferation and migration of CHS cells and facilitated their apoptosis. In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Bone Oncology ONCOLOGY-

CiteScore

7.20

自引率

2.90%

发文量

审稿时长

34 days

期刊介绍： The Journal of Bone Oncology is a peer-reviewed international journal aimed at presenting basic, translational and clinical high-quality research related to bone and cancer. As the first journal dedicated to cancer induced bone diseases, JBO welcomes original research articles, review articles, editorials and opinion pieces. Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject. The areas covered by the journal include: Bone metastases (pathophysiology, epidemiology, diagnostics, clinical features, prevention, treatment) Preclinical models of metastasis Bone microenvironment in cancer (stem cell, bone cell and cancer interactions) Bone targeted therapy (pharmacology, therapeutic targets, drug development, clinical trials, side-effects, outcome research, health economics) Cancer treatment induced bone loss (epidemiology, pathophysiology, prevention and management) Bone imaging (clinical and animal, skeletal interventional radiology) Bone biomarkers (clinical and translational applications) Radiotherapy and radio-isotopes Skeletal complications Bone pain (mechanisms and management) Orthopaedic cancer surgery Primary bone tumours Clinical guidelines Multidisciplinary care Keywords: bisphosphonate, bone, breast cancer, cancer, CTIBL, denosumab, metastasis, myeloma, osteoblast, osteoclast, osteooncology, osteo-oncology, prostate cancer, skeleton, tumour.